Skip to main content
. Author manuscript; available in PMC: 2013 Mar 15.
Published in final edited form as: J Immunol. 2012 Feb 10;188(6):2669–2676. doi: 10.4049/jimmunol.1100529

Figure 4. OVA-induced AHR and eosinophilia are strongly alleviated by treatment with sialoL.

Figure 4

BALB/c mice were sensitized by two injections (i.p.) of OVA (20 μg) and subsequently challenged with nebulized OVA in the absence or presence of sialoL (10 μg, i.v.) as outlined in (A). Airway resistance (B) and numbers of eosinophils in BAL fluid (C) were measured in mice 24h after a third airway challenge on day 30. In (B) bars represent mean ±SEM AHR and in (C) every dot represents the number of eosinophils from an individual mouse. In (B) and (C) * p<0.05 compared to chal and sens/chal + SialoL.